Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evofosfamide (Primary) ; Docetaxel; Gemcitabine; Pemetrexed
  • Indications Adenocarcinoma; Non-small cell lung cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Prostate cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Threshold Pharmaceuticals
  • Most Recent Events

    • 01 Jul 2014 Results published in a Threshold Pharmaceuticals Media Release.
    • 30 May 2012 Planned end date changed from 1 Aug 2010 to 1 Jul 2012 as reported by ClinicalTrials.gov.
    • 24 Jan 2011 Updated results from 47 patients with pancreatic cancer were presented at the ASCO Gastro Intestinal Cancers Symposium, according to a Threshold Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top